At ASINEX, we are dedicated to addressing the challenges of transforming the needs of drug discovery by creating new screening libraries which are based on our expertise in medicinal chemistry, data-driven biological predictions, and advanced computational analysis.
Since 1994 we have beenshaping the field of commercial screening libraries by committing to both quality and novelty in order to provide unmatched value to our customers and business partners.
By harnessing the powers of intelligent molecular design, advanced automated high-throughput experimentation, and ultra-fast enumeration of chemical libraries we are efficiently exploring the chemical space to identify unexplored areas of the most promising chemotypes.
By combining our expertise in cell-permeable macrocycles and bivalent molecules such as PROTACs, we are on a mission to create the world’s largest virtual library of bivalent and macrocyclic compounds that are synthetically tangible and suitable for various targets. Presently, our ultra-large virtual libraries encompass over a trillion of tangible molecules designed with the emphasis on 3 major factors: 1) synthetic feasibility 2) scalability 3) affordability.
Our parallel chemistry technology allows us to synthesize high-quality chemical libraries using solution phase, solid-phase and DNA-encoded methods, providing the most versatile options for efficient hit identification, hit-to-lead and lead optimization.
Please review our popular screening libraries to discover the products that serve your discovery programs best or contact us to explore potential collaborative and partnership opportunities.
We are a multinational company with offices and production sites located in 3 regions: North America, Europe and Japan. All company structures are involved in efficient procurement, manufacturing and distribution to deliver excellent customer service globally.
Dmitry Genis, CEO and Founder
Mr. Genis has successfully guided ASINEX from being a start-up company of 3 employees to becoming a well-recognized name in the drug discovery sector. Mr. Genis has 25+ years of experience in the areas of research, development, marketing, strategy and business operations.
Mark Parisi, Executive Director
Mr. Parisi has more than 30 years of international business experience and was instrumental in the founding and development of the company’s presence in the United States. He is responsible for the creation of multiple start-up companies and has over 16 years of experience in the life science field.
Ludmila Sadovenko, Director of Marketing Strategy
is a world-wide expert in the biotechnology industry with strength of special focus on building customer and vendor relationships. Ms Sadovenko joined ASINEX in 1995 and has held a number of roles of increasing responsibility at Asinex.
Roman Kombarov, Head of Business Development
Dr. Kombarov has more than 25 years of industry experience in both management and research positions. He has led cross-functional research teams that have advanced the discovery and lead optimization of small molecule programs in oncology, and infectious diseases in collaboration with external partners.
Shingo Ota, Asinex Japan Inc.
Mr. Ota joined ASINEX in 2003 bringing his multi-year experience in sourcing and distributing screening collections, building blocks and fine chemicals for the Japanese life science industry. Mr. Ota focuses on developing outstanding customer service and building lasting relationships with Japan-based pharmaceutical and agrochemical companies as well as academic institutions.
Toll Free: +1 877 ASINEX1
Tel: +1 336 721 1617
Fax: +1 336 721 1618
N.Chestnut St., Ste.104
Winston-Salem, NC 27101
Tel: +31 (0) 203416183
Klaprozenweg 75C, 1033NN
Amsterdam, The Netherlands
30-2 Higashihazu, Nishio,